Coloplast A/S (CPH: COLO.B)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 206.90B |
| Revenue (ttm) | 26.30B |
| Net Income (ttm) | 4.97B |
| Shares Out | 224.84M |
| EPS (ttm) | 22.09 |
| PE Ratio | 41.65 |
| Forward PE | 34.58 |
| Dividend | 21.00 (2.28%) |
| Ex-Dividend Date | May 13, 2024 |
| Volume | 410,191 |
| Open | 921.60 |
| Previous Close | 919.40 |
| Day's Range | 911.00 - 927.00 |
| 52-Week Range | 689.20 - 977.60 |
| Beta | 0.32 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2024 |
About Coloplast
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the B... [Read more]
Financial Performance
In 2023, Coloplast's revenue was 24.50 billion, an increase of 8.51% compared to the previous year's 22.58 billion. Earnings were 4.78 billion, an increase of 1.64%.
Financial StatementsNews
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons.
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons.
Coloplast A/S (CLPBF) Q3 2024 Earnings Call Transcript
Coloplast A/S (CLPBF) Q3 2024 Earnings Call Transcript
Coloplast A/S 2024 Q3 - Results - Earnings Call Presentation
Coloplast A/S 2024 Q3 - Results - Earnings Call Presentation
Coloplast A/S - Interim Financial Report, 9M 2023/24
9M 2023/24 Interim financial results, 9M 2023/24 1 October 2023 - 30 June 2024 Coloplast delivered 8% organic growth and an EBIT margin1) of 27% in Q3, with 11% growth in absolute EBIT1). Reported rev...
Coloplast A/S - Invitation to Coloplast's Meet the Management event on 6 June 2024 (gentle reminder)
The event will take place on Thursday, 6 June 2024 at Coloplast's Headquarters Holtedam 3, 3050 Humlebaek, Denmark from 11.30 - 18.00 CEST (Central European Summer Time)
Coloplast expands its Luja™ portfolio with next generation catheter for women
The female intermittent catheter enables complete bladder emptying in one free flow1, aiming to reduce the risk of urinary tract infections2.
Coloplast Finance B.V. - Interim Financial Report, H1 2023/24
H1 2023/24 Interim financial results, H1 2023/24 1 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%. Reported revenue in DKK grew 9% with...
Coloplast strengthens ostomy care portfolio with three significant product launches
The company has received reimbursement approval in the UK for Heylo™, the world's first digital leakage notification system, and expands its SenSura® Mio ostomy range with two new products.
Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H1 2023/24
H1 2023/24 Interim financial results, H1 2023/24 1 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%. Reported revenue in DKK grew 9% with ...
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Please see enclosed pdf. Attachment 08032024_trading_in_shares_LRA
Coloplast A/S - Allocation of Share Options
Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactio...
Coloplast Finance B.V. - Interim Financial Report, Q1 2023/24
Q1 2023/24 Interim financial results, Q1 2023/24 1 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin1) of 28%. Reported revenue in DKK grew 8% wi...
Coloplast launches Peristeen® Light for people with bowel disorders
The new transanal irrigation device is designed to help people facing defecation issues or stool leakage. It is estimated that 10-15% of the world's population are affected by chronic constipation1 an...
Coloplast A/S - Interim Financial Report, Q1 2023/24
Q1 2023/24 Interim financial results, Q1 2023/24 1 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin1) of 28%. Reported revenue in DKK grew 8% wi...
Coloplast launches Biatain® Silicone Fit for pressure injury prevention and wound management in the US
The company aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients.
Coloplast Finance B.V. - Change of Auditor
Today, 24 January 2024, Coloplast Finance B.V. held its Annual General Meeting at which Ernst & Young Accountants LLP was elected as Coloplast Finance B.V.'s auditors.
Coloplast Finance B.V. - Decisions at the Annual General Meeting
On 24 January 2024, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2022/2...
Coloplast A/S - Q1 2023/24 Earnings Release - Invitation for conference call on 9 February 2024 at 11.00am CET
Friday, 9 February 2024 at 11.00 - 12.00 CET In connection with the publication of Coloplast's interim financial results for Q1 2023/24, to be released same day around 07.30 am CET, Coloplast will hos...
Coloplast A/S - Change of auditor
Today, 7 December 2023, Coloplast A/S held its Annual General Meeting, at which EY Godkendt Revisionspartnerselskab was elected as Coloplast A/S' auditors in line with the proposal from the Board of D...
Coloplast A/S - Articles of Association
Articles of association for Coloplast A/S as adopted at the Annual General Meeting of Coloplast A/S held today, 7 December 2023 are enclosed. For further information, please contact Investors and anal...
Coloplast A/S - Decisions at the Annual General Meeting 2023
Today, 7 December 2023, Cololast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2022/23 was approved. Distribution of ye...
Coloplast A/S - Notice of Annual General Meeting 2023
The Annual General Meeting of Coloplast A/S will be held on Thursday, 7 December 2023 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humleb...